Open-Label Comparative Clinical Study of Chlorproguanil−Dapsone Fixed Dose Combination (Lapdap™) Alone or with Three Different Doses of Artesunate for Uncomplicated Plasmodium falciparum Malaria
Daniel G. Wootton, Hyginus Opara, Giancarlo A. Biagini et al. · 2008
Read Open-Label Comparative Clinical Study of Chlorproguanil−Dapsone Fixed Dose Combination (Lapdap™) Alone or with Three Different Doses of Artesunate for Uncomplicated Plasmodium falciparum Malaria by Daniel G. Wootton, Hyginus Opara, Giancarlo A. Biagini et al. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0001779.txt.
Description
Daniel G. Wootton, Hyginus Opara, Giancarlo A. Biagini, and their co-authors ran a malaria drug dosing trial in a 2008 PLOS ONE research article. The aim was to find the right dose of artesunate to pair with chlorproguanil-dapsone, sold as Lapdap, a fixed-dose drug for uncomplicated Plasmodium falciparum malaria. Dosing matters: too little fails to cure and breeds resistance, too much adds side effects.
The open-label trial compared Lapdap alone against Lapdap with three different artesunate doses. The full text gives the cure rates and safety results for each arm. Combination therapy is the global standard for falciparum malaria, so dose-finding trials like this one write the recipe that clinics follow.
Catalog record
| CREATOR | Daniel G. Wootton, Hyginus Opara, Giancarlo A. Biagini et al. |
|---|---|
| YEAR | 2008 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 70 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0001779